Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724289 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin for Prolonged Grief Disorder
A Early Phase 1 study of Prolonged Grief Disorder, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06724289 is a Early Phase 1 study of Prolonged Grief Disorder that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 12 participants, below the 208-participant average among 3 other Prolonged Grief Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06724289, a Early Phase 1 study of Prolonged Grief Disorder, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
- DIAGNOSTIC_TEST Functional Magnetic Resonance Imaging (fMRI)
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06724289
The ClinicalTrials.gov registry entry for NCT06724289 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 3 other Prolonged Grief Disorder trials with a reported enrollment target (94% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prolonged Grief Disorder appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin 25 mg is the first listed.
NCT06724289 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06724289 about?
NCT06724289 is a clinical study titled "Psilocybin for Prolonged Grief Disorder". The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
What is the current status of trial NCT06724289?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2027-08.
What conditions does trial NCT06724289 study?
This clinical trial studies the following conditions: Prolonged Grief Disorder.
What interventions are being tested in trial NCT06724289?
The interventions under investigation include: Psilocybin 25 mg (DRUG), Functional Magnetic Resonance Imaging (fMRI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06724289?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724289 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prolonged Grief Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.